Siege Pharmaceuticals is structured around development of new cancer drugs that is based on a naturally-occurring molecule that functions by effectively starving cancer cells to death. A common occurence in use of many existing cancer therapies is that the cancers develop resistance. The drugs under development by Siege are synthetic variants with optimized drug-like properties. Effectively, the approach one that it premised onthe assumption that by targeting multiple pathways that cancer cells need for growth, that resistance would be lessened/undermined
